Form 8-K Stereotaxis, Inc. For: Dec 18
�
�
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
�
�
FORM 8-K
�
�
CURRENT REPORT
PURSUANT TO SECTION�13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December�18, 2014
�
�
STEREOTAXIS, INC.
(Exact Name of Registrant as Specified in Its Charter)
�
�
�
Delaware | � | 001-36159 | � | 94-3120386 |
(State or Other Jurisdiction of Incorporation) |
� | (Commission File Number) |
� | (IRS Employer Identification No.) |
�
4320 Forest Park Avenue, Suite 100, St. Louis, Missouri | � | 63108 |
(Address of Principal Executive Offices) | � | (Zip Code) |
(314) 678-6100
(Registrant�s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
�
�
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
�
� | � | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
�
� | � | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
�
� | � | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
�
� | � | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
�
�
�
Item�8.01. | Other Events |
Stereotaxis, Inc. (the �Company�) was granted 510(k) clearance by the Food and Drug Administration on December�18, 2014, to market its Vdrive� with V-CAS� Catheter Advancement System in the U.S. The Company also has received regulatory approval of its Odyssey� system by the Japan Pharmaceuticals and Medical Devices Agency.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
�
� | � | � | STEREOTAXIS, INC. | |||
Date: January�5, 2015 | � | � | By: | � | /s/ Karen Witte Duros | |
� | � | Name: | � | Karen Witte Duros | ||
� | � | Title: | � | Sr. Vice President, General Counsel |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
- OpenGate Capital Completes Sale of SMAC
- Transaction in Own Shares
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!